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ABSTRACT
Mitochondrial fatty acid ß-oxidation disorders are a group of clinically and
biochemically heterogeneous defects mainly associated with intolerance to catabolic
stress. The diseases are potentially fatal, but treatable and the prognosis for most
diagnosed disorders is generally favourable. Early diagnosis is thus important to prevent
morbidity and mortality.
This project describes an improved and validated quantitative fibroblast
acylcarnitine profile assay for the investigation of suspected fatty acid ß-oxidation
disorders. Intact cells were incubated with deuterium-labelled hexadecanoate and
L-carnitine, and the accumulated acylcarnitines in the medium analysed using
electrospray tandem mass spectrometry. This modified procedure is less demanding
technically, requires fewer cells and better reflects the in vivo acylcarnitine status than
previously published methods.
Mitochondrial fatty acid ß-oxidation is coupled to the respiratory chain.
Functional defects of one pathway may lead to secondary alterations in flux through the
other. The diagnostic specificity and the prognostic potential of the in vitro acylcarnitine
profile assay were investigated in fibroblasts from 14 normal controls, 38 patients with
eight enzyme deficiencies of fatty acid ß-oxidation presenting with various phenotypes,
and 16 patients with primary respiratory chain defects including both isolated and
multiple enzyme complex defects. All fatty acid ß-oxidation deficient cell lines revealed
disease-specific acylcarnitine profiles related to the sites of defects irrespective of the
severity of symptoms or of different mutation. Preliminary studies suggested a
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correlation between severity of symptoms and higher concentrations of long-chain
acylcarnitine species. However, the fibroblast acylcarnitine profiles from some patients
with respiratory chain defects were similar to those of controls, whereas others had
abnormal profiles resembling those found in fatty acid ß-oxidation disorders.
In vitro acylcarnitine profiling is useful for the detection of fatty acid ß-oxidation
deficiencies, and perhaps the prediction of disease severity and prognostic evaluation
facilitating decisions of therapeutic intervention and genetic counselling. However,
abnormal profiles do not exclusively indicate these disorders, and primary defects of the
respiratory chain remain a possibility. Awareness of this diagnostic pitfall will aid in the
selection of subsequent confirmatory tests and therapeutic options.
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